Vertex to host conference call Conference call to discuss Phase 2 study of VX-809 and additional updates to the company's CF research and development program will be held on October 11 at 6:30 pm. Webcast Link
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Stocks with call strike movement; FSLR VRTX First Solar (FSLR) March 80 call option implied volatility increased 2% to 42, Vertex (VRTX) January 105 call option implied volatility increased 6% to 41 according to IVolatility.
Vertex upgraded to Buy from Neutral at Goldman Goldman Sachs upgraded Vertex Pharmaceuticals to Buy saying it sees a 90% probability of approval for the company's VX-809/Kalydeco combo for cystic fibrosis and a higher likelihood of M&A following the positive Phase 3 data in June. Goldman raised its price target for shares to $131 from $109.